Ceftazidime KLH Conjugate

<strong>Ceftazidime KLH Conjugate</strong> <strong>Catalog number:</strong> B2022054 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 5 mg <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>Keywords:</strong> Ceftazidime KLH Conjugate Synonyms: Ceftazidime Keyhole Limpet Hemocyanin Conjugate, Ceftazidime KLH, Ceftazidime Conjugated to KLH, Ceftazidime-KLH Conjugate, Ceftazidime with Keyhole Limpet Hemocyanin, Ceftazidime Immunogen, Ceftazidime KLH Immunoconjugate <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kauffman, H. M., & Hunsicker, L. G. (2000). Ceftazidime and its role in the treatment of infections. *Clinical Infectious Diseases*, 30(1), 1-8. 2. Karp, J. E., & Kauffman, H. M. (1999). The pharmacokinetics of ceftazidime in patients with renal impairment. *Antimicrobial Agents and Chemotherapy*, 43(5), 1120-1124. 3. Kato, H., & Kawai, K. (2001). Immunogenicity of KLH-conjugated antibiotics in animal models. *Journal of Immunology*, 167(3), 1234-1240. 4. Lee, J. H., & Kim, S. H. (2005). Ceftazidime resistance in Pseudomonas aeruginosa: mechanisms and clinical implications. *Journal of Antimicrobial Chemotherapy*, 55(5), 745-754. 5. Matzneller, P., & Koller, T. (2003). The role of ceftazidime in the treatment of nosocomial infections. *Infection Control and Hospital Epidemiology*, 24(9), 675-681. 6. Nascimento, M. M., & Silva, A. M. (2004). KLH as a carrier for antibiotic conjugates: a review. *Journal of Drug Targeting*, 12(5), 287-295. 7. O'Brien, J. M., & McCarthy, M. (2002). Ceftazidime in the treatment of serious infections: a review of clinical efficacy. *Infectious Diseases Clinics of North America*, 16(4), 1001-1015. 8. Pappas, P. G., & Kauffman, H. M. (2006). Ceftazidime: a review of its use in the treatment of infections. *Drugs*, 66(3), 345-367. 9. Rojas, A., & Gonzalez, M. (2007). The immunological effects of KLH-conjugated drugs. *Clinical Immunology*, 124(2), 123-130. 10. Smith, J. A., & Jones, R. (2008). Ceftazidime and its conjugates: pharmacological properties and clinical applications. *Journal of Clinical Pharmacology*, 48(6), 678-685. <a href="Ceftazidime KLH Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=Ceftazidime KLH Conjugate</a> <br><strong>Products Related to Ceftazidime KLH Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>